Kingsview Wealth Management, LLC Akebia Therapeutics, Inc. Transaction History

Kingsview Wealth Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 17, 2022	SELL	$2.26 - $3.34 $24,767 - $36,603	-10,959 Closed	0 $0
Q3 2021 Dec 03, 2021	SELL	$2.35 - $3.88 $8,095 - $13,366	-3,445 Reduced 23.92%	10,959 $32,000
Q2 2021 Aug 17, 2021	SELL	$2.83 - $4.2 $3,562 - $5,287	-1,259 Reduced 8.04%	14,404 $56,000
Q1 2021 May 24, 2021	SELL	$2.92 - $5.06 $1,019 - $1,765	-349 Reduced 2.18%	15,663 $52,000
Q4 2020 Feb 16, 2021	BUY	$2.22 - $3.78 $6,882 - $11,718	3,100 Added 24.01%	16,012 $45,000
Q3 2020 Nov 19, 2020	BUY	$2.39 - $13.08 $6,453 - $35,316	2,700 Added 26.44%	12,912 $32,000
Q2 2020 Aug 14, 2020	BUY	$6.67 - $13.58 $68,114 - $138,678	10,212 New	10,212 $139,000
Q3 2019 Jan 29, 2020	SELL	$3.55 - $5.4 $38,613 - $58,735	-10,877 Closed	0 $0
Q2 2019 Jan 29, 2020	SELL	$4.1 - $8.05 $766 - $1,505	-187 Reduced 1.69%	10,877 $53,000
Q1 2019 Jan 29, 2020	BUY	$5.41 - $8.73 $59,856 - $96,588	11,064 New	11,064 $91,000

120

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $324M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Kingsview Wealth Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Kingsview Wealth Management, LLC with notifications on news.